Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.620 -0.210 (-5.48%)

Streaming Delayed Price Updated: 3:20 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 20, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

January 04, 2024

From ADC Therapeutics SA

Via GlobeNewswire

Analyst Expectations for ADC Therapeutics's Future ↗

November 20, 2023

Via Benzinga

The Latest Analyst Ratings for ADC Therapeutics ↗

September 12, 2023

Via Benzinga

ADC Therapeutics Provides Business Updates

January 04, 2024

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

December 12, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

November 07, 2023

From ADC Therapeutics SA

Via GlobeNewswire

A Preview Of ADC Therapeutics's Earnings ↗

August 07, 2023

Via Benzinga

4 Analysts Have This to Say About ADC Therapeutics ↗

July 25, 2023

Via Benzinga

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 07, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger...

Via Benzinga

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

November 06, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

November 02, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

October 24, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics to Participate in September Investor Conferences

September 05, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

August 30, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗

August 10, 2023

Via Benzinga

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 08, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

August 01, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

July 24, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths ↗

July 21, 2023

ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...

Via Benzinga

ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

July 20, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher ↗

July 11, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P...

Via Benzinga

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 11, 2023

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.

Via Benzinga

Crude Oil Rises 2%; ADC Therapeutics Shares Plummet ↗

July 11, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.